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Abstract
Background: We aimed to assess whether high-dose preoperative chemoradiotherapy (CRT) improves outcome in 
esophageal cancer patients compared to surgery alone and to define possible prognostic factors for overall survival.
Methods: Hundred-and-seven patients with disease stage IIA - III were treated with either surgery alone (n = 45) or 
high-dose preoperative CRT (n = 62). The data were collected retrospectively. Sixty-seven patients had 
adenocarcinomas, 39 squamous cell carcinomas and one undifferentiated carcinoma. CRT was given as three intensive 
chemotherapy courses by cisplatin 100 mg/m2 on day 1 and 5-fluorouracil 1000 mg/m2/day, from day 1 through day 5 
as continuous infusion. One course was given every 21 days. The last two courses were given concurrent with high-
dose radiotherapy, 2 Gy/fraction and a median dose of 66 Gy. Kaplan-Meier survival analysis with log rank test was used 
to obtain survival data and Cox Regression multivariate analysis was used to define prognostic factors for overall 
survival.
Results: Toxicity grade 3 of CRT occurred in 30 (48.4%) patients and grade 4 in 24 (38.7%) patients of 62 patients. One 
patient died of neutropenic infection (grade 5). Fifty percent (31 patients) in the CRT group did undergo the planned 
surgery. Postoperative mortality rate was 9% and 10% in the surgery alone and CRT+ surgery groups, respectively (p = 
1.0). Median overall survival was 11.1 and 31.4 months in the surgery alone and CRT+ surgery groups, respectively (log 
rank test, p = 0.042). In the surgery alone group one, 3 and 5 year survival rates were 44%, 24% and 16%, respectively 
and in the CRT+ surgery group they were 68%, 44% and 29%, respectively. By multivariate analysis we found that age of 
patient, performance status, alcoholism and > = 4 pathological positive lymph nodes in resected specimen were 
significantly associated with overall survival, whereas high-dose preoperative CRT was not.
Conclusion: We found no significant survival advantage in esophageal cancer stage IIA-III following preoperative high-
dose CRT compared to surgery alone. Patient's age, performance status, alcohol abuse and number of positive lymph 
nodes were prognostic factors for overall survival.
Introduction
Patients with esophageal cancer continue to have a poor
prognosis with a 5 year survival rate less than 20%. Sev-
eral factors contribute to this poor outcome, of which the
most important is that the vast majority of patients dem-
onstrate either locally advanced or metastatic disease at
the time of diagnosis. Surgery has been relatively unsuc-
cessful in controlling loco-regionally-advanced tumors
and preoperative concomitant chemotherapy with radio-
therapy (RT) followed by resection has become a treat-
ment option. Several studies [1-3] have shown that the
prognosis for esophageal cancer patients undergoing sur-
gery might be improved due to the effect of preoperative
concomitant chemoradiotherapy (CRT), whereas others
have not found any survival benefit by preoperative CRT
over surgery alone [4-8]. However, local recurrence and
distant metastases remain an issue both after surgery
alone and after CRT followed by surgery. In an attempt to
improve survival rates, high-dose preoperative CRT was
implemented in our hospital from 1996. The applied che-
motherapy regimen was originally introduced for the
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head and neck, the so-called "Wayne State Regimen" [9].
Improved complete response and survival rates were
reported with this regimen which applied cisplatin 100
mg/m2 day 1 and 5-Fluorouracil 1000 mg/m2/day, day 1-5
as continuous infusion. Some studies have also suggested
a possible positive effect on local tumor control by
increasing the RT dose [10-12]. We therefore applied
high-dose RT concomitant with intensive chemotherapy
(Wayne State Regimen) in an attempt to improve out-
come.
The purpose of this study was to investigate the effect
of dose intensification of preoperative CRT on overall
survival compared to the outcome of surgery alone and
possibly also to identify prognostic factors that might
influence overall survival.
Patients and Methods
Two-hundred and one esophageal cancer patients were
entered into the database at Haukeland University Hospi-
tal, Bergen, Norway during the period 1996 to 2007. In
this study we excluded 94 patients due to disease stage 0,
I and IV (n = 54), only RT ± surgery (n = 17), definitive
CRT due to medical contraindication of surgery (n = 17),
only chemotherapy preoperatively (n = 2), different his-
tology than carcinomas (n = 2), sequential chemotherapy
and RT preoperatively (n = 1), and gastric cancer during
autopsy (n = 1).
The remaining 107 patients were treated with surgery
alone (45) or preoperative concomitant high-dose CRT
(62). The patients were assigned to surgery alone or CRT
followed by surgery according to physician and patient
preferences, mainly because survival benefits from pre-
operative CRT in this study period was considered con-
troversial. Forty-six of 62 patients receiving CRT were
deemed resectable before starting CRT and 16 of 62 with
T4 tumors deemed resectable pending response to CRT
and shrinkage.
Staging of the tumors was performed according to
UICC classification (2002) [13] by endoscopic ultra-
sonography (EUS) and computed tomography (CT) scans
of the chest and abdomen. Bronchoscopy was performed
in proximally located tumors. Physiological assessment
included routine hematological and biochemical assays.
Adequate renal and liver functions were required before
treatment.
The CRT protocol included three intensive chemother-
apy courses concurrent with high-dose RT (66 Gy). Each
chemotherapy course consisted of cisplatin 100 mg/m2,
intravenous infusion over four hours on day 1, and 5-Flu-
orouracil 1000 mg/m2/day as intravenous continuous
infusion, on day 1 through day 5. The chemotherapy
course was repeated on day 22 and 43. RT was given con-
comitantly with the second and third chemotherapy
courses and was applied as 2 Gy per fraction, 5 fractions
per week, 33 fractions in 6.5 weeks to a total dose of 66
Gy. RT was given as CT-based conformal 4 fields' treat-
ment in two phases. Phase 1 RT was given with two ante-
rior-posterior parallel-opposed fields and two lateral
oblique fields giving 50 Gy, taking into account the nor-
mal tissue tolerance of the spinal cord, heart and lungs.
The additional 16 Gy were given using the same four
fields, but with different angles for the lateral oblique
fields. The gross tumor volume (GTV) was drawn
directly onto the axial planning CT images using outlines
of the defined primary tumor and nodal disease obtained
from the EUS and CT scans. The delineated GTV was the
macroscopic tumor including possible macroscopic path-
ological lymph nodes. The cranial and caudal margins
were 3 cm from the GTV and the radial margin was 1.5
cm in the first phase of treatment (50 Gy). After treat-
ment with 50 Gy the radial, cranial and caudal margins
were reduced to 1 cm and additional 16 Gy to a total dose
of 66 Gy were given. There was no time interval between
the two RT phases. About one month following the com-
pletion of CRT, a chest and abdomen CT scan and EUS
were performed to evaluate treatment outcome.
Toxicities were evaluated and graded according to the
National Cancer Institute (NCI) Common Terminology
Criteria, version 3.0 [14].
The patients were operated with a right-sided transtho-
racic or a transhiatal total esophagectomy. All patients
had a two-field lymph node resection and left-sided cer-
vical anastomosis, hand-sewn or stapled as of the deci-
sion of the surgeon. Most patients had a feeding catheter
jejunostomy and feeding was started the day after the
operation and continued for 7 - 12 days. All patients had a
clinical follow up and underwent radiological and/or
endoscopic surveillance when indicated.
Statistical Analysis
Statistical comparisons between the surgery alone and
CRT groups were done with exact chi-square tests and
independent samples t tests for nominal and continuous
variables, respectively. Exact Mann-Whitney U test was
used for comparing ordinal as well as unevenly distrib-
uted continuous variables. Univariate assessments of cat-
egorical prognostic factors for survival and survival
analysis were performed using the Kaplan-Meier method
with log-rank tests, while continuous risk factors for sur-
vival were analyzed by Cox regression survival analysis.
Variables tested for possible influence on survival in
univariate analysis were age, gender, smoking, alcohol-
ism, heart disease, lung disease, diabetes mellitus, perfor-
mance status, hemoglobin level, histology, histological
differentiation, tumor (T)-stage at diagnosis, lymph node
(N)-stage at diagnosis, disease stage at diagnosis, tumor
length, tumor location in esophagus, preoperative CRT,
Hurmuzlu et al. World Journal of Surgical Oncology 2010, 8:46
http://www.wjso.com/content/8/1/46
Page 3 of 9operation method (transthoracic versus transhiatal resec-
tion), number of lymph nodes with metastases in
resected specimen (no lymph node metastasis, 1-3 nodes
with metastasis or 4 or more nodes with metastasis).
Factors found to be significant at univariate analyses
were included in multivariate Cox regression survival
analysis.
The survival time was calculated from start of treat-
ment (CRT or surgery) to the date of death or to censor-
ing in May 1st 2009.
All p-values are from 2-sided tests, p value ≤ 0.05 was
considered statistically significant. All statistical analyses
were performed by SPSS 15.0 (SPSS Inc., Chicago, IL,
USA). The study was approved by The Regional Commit-
tee for Research Ethics in Western Norway.
Results
Of the 107 patients included in the study there were 94
men and 13 women (median age 65 years, range 39-83).
Thirty-nine had squamous cell carcinomas, 67 adenocar-
cinomas and one had undifferentiated carcinoma. Gen-
eral pretreatment characteristics are shown in Table 1.
There were more smokers in the CRT group than in the
surgery alone group (55% versus 34%, p = 0.048) whereas
comorbidities (heart disease, lung disease, and diabetes
mellitus) and alcoholism were similar in both groups.
Forty-nine patients (79%) received the planned 66 Gy,
nine patients (14.5%) received from 60-64 Gy, whereas
four patients (6.4%) received between 47.5 and 56 Gy.
The mean and median delivered dose-intensities of cispl-
atin were 84% and 90% of the planned dose, respectively,
while mean and median doses of 5-fluorouracil were 86%
and 90%, respectively. All chemotherapy dose reductions
were due to toxicity.
Median time from end of preoperative CRT to surgical
resection was 9 weeks (range 4 to 23 weeks) for patients
who were operated on.
CRT toxicity
CRT toxicity grade 3 occurred in 30 of 62 patients (48.4%)
and grade 4 in 24 of 62 patients (38.7%). Toxicity grade 5
(death) occurred in one patient. This patient had grade 5
leucopenia, grade 5 neutropenia, grade 5 thrombocy-
topenia and died of neutropenic infection after com-
pleted CRT.
The following CRT toxicities occurred as both grade 3
and 4: Leucopenia (37 patients), neutropenia (34
patients), neutropenic infection (13 patients), thrombo-
cytopenia (20 patients) and reduced performance status
(20 patients).
CRT toxicities that occurred as grade 3 only were
esophagitis (35 patients), stomatitis (12 patients),
anorexia (23 patients), nausea (22 patients), vomiting (5
patients) and anemia in one patient. Each patient might
have several types of toxicity.
Resectability
Fifty percent (31 patients) in the CRT group did not
undergo the planned surgery. The reason for this was still
T4 tumor after response to CRT (8), reduced perfor-
mance status after CRT (8), cerebrovascular accident dur-
ing the CRT (1), esophageal fistula and technical
difficulties (1) and progression of disease with inoperabil-
ity (13).
In the surgery alone group 25 patients (55.6%) were
operated by transthoracic esophagectomy (TTE) and 20
(44.4%) by transhiatal esophagectomy (THE), whereas in
the CRT group 29 patients (46.8%) were operated by
TTE, 31 (50%) were not operated, one underwent a by-
pass operation due to fistula and one underwent abdomi-
nal exploration only due to peritoneal carcinomatosis.
In the surgery alone group, 38 of 45 patients (84.4%)
had a curative resection defined as no macroscopic and
microscopic residual tumors and negative resection mar-
gins (R0), six patients (13.3%) had microscopic positive
margin in the resected specimen (R1) and one (2.2%) had
macroscopic residual disease (R2 resection) with infiltra-
tion in the trachea.
Among the 31 operated patients in the CRT group 26
(84% of 31 patients) had R0 resections, three (10%) had
R1 resections and two patients (6.4%) had R2 resections.
Response to CRT
Comparison of stage of disease before and after treatment
in 31 operated CRT patients demonstrated down-staging
in 58%, no change in 23% and up-staging in 19% of the
patients (Figure 1 and Table 2).
Histopathological evaluation of the 31 operated CRT
patients demonstrated that 10 patients (32.2%) had path-
ological complete response (pCR) and 3 patients demon-
strated a T0 tumor with 1 or 2 lymph nodes with residual
metastasis.
Patients having CRT and not undergoing surgery (31)
could only be evaluated clinically. In these patients we
found complete response in two (6.4% of 31), partial
response in 14 (45.2%) and stable disease in one (3.2%).
Progression of the disease was seen in 13 patients (42%)
whereof nine had distant metastasis. One patient was not
evaluated by CT/EUS after CRT, but had no clinical signs
of progressive disease.
In the surgery alone group there was a perfect concor-
dance between preoperative clinical staging and the post-
operative pathological staging (Figure 1).
Postoperative mortality and morbidity
Postoperative mortality and morbidities occurred during
30 days after operation or during the same hospital stay
are listed in Table 3. We found no significant differences
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groups.
Survival
At time of analysis, 89 of 107 patients had died; follow up
time was median 13.6 months for all 107 patients. Dead
patients were followed up until death and the alive
patients had a median follow-up of 95 months (range 21 -
137 months).
Survival rates for surgery alone (n = 45) and CRT fol-
lowed by surgery (n = 31) are listed in Table 4. Median
overall survival was 11.1 and 31.4 months in the surgery
alone and the CRT+ surgery groups, respectively.
By univariate analysis we found that a favorable overall
survival was associated with preoperative CRT (p = 0.042,
Figure 2), younger age (p = 0.017), better performance
status (p < 0.001), no alcoholism (p = 0.028) and TTE (p =
0.048). In addition, ≥ 4 pathologically positive lymph
nodes in resected specimens were a negative prognostic
factor for survival (p < 0.001, Figure 3). We found no
effect on survival of age, gender, smoking, alcoholism,
heart disease, lung disease, diabetes mellitus, perfor-
mance status, hemoglobin level, histology, histological
differentiation, T-stage at diagnosis, N-stage at diagnosis,
disease stage at diagnosis, tumor length and tumor loca-
tion in esophagus.
Multivariate analysis showed, however, that age, perfor-
mance status, alcohol abuse and number of lymph nodes
with metastases in operation specimen were significantly
associated with overall survival (Table 5).
Comparing the incidence and type of disease recur-
rence in the two treatment groups showed a higher rate of
distant metastases in surgery alone group (Table 6).
Discussion
In this study, the high-dose preoperative CRT did not
demonstrate a significant survival benefit compared to
surgery alone by multivariate analysis, although CRT+
surgery patients had longer survival. Several randomized
studies have also failed to show a survival advantage fol-
lowing neoadjuvant CRT [4,5,7] and our results are con-
sistent with them although we applied high-dose CRT.
Furthermore, we found that age, performance status,
alcoholism and number of positive lymph nodes were sig-
nificantly associated with overall survival.
Table 1: Pretreatment characteristics in 107 esophageal cancer patients.
Surgery alone
n = 45
#CRT ± surgery
n = 62
p Surgery alone
n = 45
CRT+ surgery
n = 31
p
Male/Female 41/4 53/9 0.55 41/4 27/4 0.71
Age median (range), yr 69 (39-83) 63 (46-79) 0.22 69 (39-83) 58 (46-79) 0.032
† PS WHO 0 9 (20) 16 (25.8) 0.60 9 (20) 10 (32.3) 0.08
PS WHO 1 31 (68.9) 42 (67.7) 31 (68.9) 21 (67.7)
PS WHO 2 5 (11.1) 4 (6.5) 5 (11.1) 0
Tumor length median 
(range) cm
5 (1-11.5) 6 (1-12) 0.033 5 (1-11.5) 6 (3-12) 0.035
Upper thoracic tumor 1 (2.2) 10 (16.1) <0.001 1 (2.2) 1 (3.2) 0.68
Middle thoracic tumor 6 (13.3) 24 (38.7) 6 (13.3) 7 (22.6)
Lower thoracic tumor 38 (84.4) 28 (45.2) 38 (84.4) 23 (74.2)
¶ SCC 7 (15.9) 32 (51.6) <0.001 7 (15.9) 10 (32.3) 0.16
Adenocarcinoma 37 (84.1) 30 (48.4) 37 (84.1) 21 (67.7)
Disease stage IIA 19 (42.2) 14 (22.6) 0.028 19 (42.2) 8 (25.8) 0.24
Disease stage IIB 6 (13.3) 8 (12.9) 6 (13.3) 6 (19.4)
Disease stage III 20 (44.4) 40 (64.5) 20 (44.4) 17 (54.8)
Clinical ‡ T1 0 (0) 2 (3.2) 0.072 0 (0) 1 (3.2) 0.84
Clinical T2 15 (33.3) 13 (21.0) 15 (33.3) 10 (32.3)
Clinical T3 26 (57.8) 31 (50.0) 26 (57.8) 17 (54.8)
Clinical T4 4 (8.9) 16 (25.8) 4 (8.9) 3 (9.7)
Clinical § N1 24 (53.3) 42 (73.7) 0.039 24 (53.3) 22 (71) 0.031
# Chemoradiotherapy. † Performance status. ¶ Squamous cell carcinoma ‡Tumor stage, §lymph node stage. One patient in surgery alone group 
had undifferentiated carcinoma. Percentages in parentheses if not other stated.
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response and down-staging of primary tumors, lymph
node metastases and combined TNM stages in both
operated and non-operated patients (Figure 1, Table 2).
This is consistent with report of Kesler et al [15] who
have shown that preoperative CRT causes down-staging
in esophageal cancer.
In addition, we found that lymph node status is a pre-
dictor of outcome where patients with ≥ 4 positive lymph
nodes have poorest survival (Figure 3). This is confirmed
by previous studies [15-18].
The preoperative CRT was strongly correlated with
lymph node stage in resected specimens; this simultane-
ously with limited number of patients in this study might
be factors that contributed to a non-significant p-value of
preoperative high-dose CRT when both CRT and num-
ber of positive lymph nodes were included in the multi-
variate Cox regression analysis.
Further, we found no difference in local tumor control
between the two treatment groups, and the median local
recurrence free survival (survival from treatment start
until disease recurrence in the field of radiotherapy and/
or field of surgery in the mediastinum) was not reached
in both groups (Table 4). The role of CRT and surgery in
Figure 1 Stage of disease at diagnosis and after operation; 45 sur-
gery alone and 31 chemoradiotherapy + surgery patients. CRT = 
chemoradiotherapy.
Table 2: Final histopathological stages of tumors and lymph nodes in resected specimens according to treatment group.
Surgery alone
(n = 45)
Chemoradiotherapy+ Surgery
(n = 31)#
p value
Pathologic † T0 (%) 0 13 ‡ (41.9) < 0.001
Pathologic T1 (%) 1 (2.2) 2 (6.5)
Pathologic T2 (%) 13 (29.0) 8 (25.8)
Pathologic T3 (%) 29 (64.4) 7 (22.6)
Pathologic T4 (%) 2 (4.4) 0
Pathologic § N0 (%) 13 (29) 18 (58) 0.027
Pathologic N1, 1-3 positive nodes (%) 19 (42) 9 (29)
Pathologic N1, ≥ 4 positive nodes (%) 13 (29) 3 (10)
Pathologic ¶ M1 (%) 0 2 (6.4)
# One patient in the chemoradiotherapy group who had peritoneal carcinomatosis during operation did not undergo esophagectomy (= 
TXNX). † Tumor stage. ‡ Three of these 13 patients had lymph node metastasis. § Lymph node stage.¶ Distant metastasis.
Table 3: Postoperative mortality and morbidities in 76 
esophageal cancer patients.
Complication Surgery 
alone, n = 45
‡CRT+ surgery, 
n = 31
P value
Postoperative 
complications
33 25 0.59
Respiratory failure 20 14 1.0
Pneumonia 19 14 0.82
Anastomosis leakage 5 2 0.69
Wound infection 5 4 1.0
Recurrent laryngeal 
nerve paralysis
6 5 0.75
Thromboembolism 2 1 1.0
Tracheal injury 0 1 0.41
Bleeding 2 1 1.0
Intraabdominal 
abscess
1 0 1.0
Chylothorax 0 1 0.41
Other complications 13 9 1.0
Postoperative 
mortality
4 (9%) 3 (10%) 1.0
‡ Chemoradiotherapy.
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However, it should be noted that patients in the CRT
group had more lymph node metastases, more advanced
stage of disease and longer tumors at diagnosis compared
to the surgery alone group. According to this we might
expect that preoperative CRT had contributed to an
improved local tumor control. At the same time our find-
ings of residual tumors in resected specimens in a large
proportion of patients having R0-resections after CRT
indicate that esophagectomy is advisable after CRT if R0
resection is possible. Hence, we conclude that both pre-
operative CRT and radical surgery with extensive lymph
node dissection are essential to obtain a good local tumor
control.
Our study has, however, some limitations and the
results should be interpreted with caution. The study was
retrospective with limited number of patients and the
treatment groups included both adenocarcinomas and
squamous cell carcinomas. This is because at the time of
this study, from 1996, the treatment of both histologies
was almost the same and only last years the experts are
trying to treat them differently.
Another finding in our study was that the high-dose
preoperative CRT group had a much higher frequency of
serious toxicities compared to other studies applying
Table 4: Survival data in 76 esophageal cancer patients (time in months).
Surgery 95% CI †
‡ CRT + Surgery 95% CI p
No. of patients 45 31
Overall survival (median) 11.1 7.63 - 14.53 31.4 11.90-50.98 0.042
Disease-specific survival (median) 11.1 7.63 - 14.53 34.4 6.88-61.91 0.019
Progression free survival (median) 9.5 7.36 - 11.63 18.0 8.48 - 27.52 0.064
DMFS ¶ (median) 9.6 6.75 - 12.50 17.94 6.39 - 29.48 0.058
# LR free survival (median) X X 0.67
Patients free of LR after 3 years 69% 71%
Patients free of LR after 5 years 61% 71%
1 year overall survival rate 44% 68%
3 year overall survival rate 24% 44%
5 year overall survival rate 16% 29%
† Confidence interval. ‡ Chemoradiotherapy. ¶ Distant metastasis free survival. # Local recurrence. X = not reached. Local recurrence free 
survival stands for survival from treatment start until disease recurrence in the field of radiotherapy and/or field of surgery in the 
mediastinum.
Figure 2 Overall survival in esophageal cancer following surgery 
alone or chemoradiotherapy + surgery. CRT = chemoradiotherapy. 
Univariate analysis.
Figure 3 Survival versus number of lymph node metastasis in re-
sected specimens in 76 esophageal cancer patients.
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RT [21-25]. This should be taken into consideration in
further neoadjuvant regimens for esophageal cancer
patients.
The main reason for the inferior survival in esophageal
cancer patients generally is the early and frequent occur-
rence of distant metastases. This was also found in our
study, as we found a high proportion of distant metastasis
in both treatment groups, and highest in the surgery
alone group. It is obvious that refinements of chemother-
apy or new and more effective systemic treatments,
which are able to treat subclinical metastases, are
required for these patients.
The observed survival rate in the 31 CRT+ surgery
patients in our series was not superior to what is reported
in published series which applied lower doses of preoper-
ative CRT [2,5,6,8,15,19,22,26-30]. Due to different
patient populations in reported series comparisons
between various treatment regimens should be inter-
preted with caution. However, based on our study and
other reported series with pretreatment factors compara-
ble to ours using lower doses of cisplatin and 5-fluoroura-
cil concomitant with RT [2,5,8,15,19,27-30] it is evident
that higher doses of CRT is not superior to conventional
doses and also have increased toxicities. In consistence
with the RTOG 94-05 trial [23] which was published in
2002 we do not recommend high-dose preoperative CRT
outside clinical trails.
Conclusion
Our high-dose preoperative CRT did not show a signifi-
cant survival advantage over surgery alone and over what
is reported in previous studies applying cisplatin, 5-Fluo-
rouracil and RT in conventional doses. Development of
new cytotoxic regimens or other systemic therapies are
required in order to cure subclinical distant metastases
and significantly improve the prognosis. Age, perfor-
mance status, alcohol abuse and number of positive
Table 5: Prognostic factors for overall survival in 76 esophageal cancer patients (multivariate Cox regression analysis).
Factors † HR 95% CI ‡ p value
Age 1.04 1.00 1.07 0.029
Performance status WHO grad 0 1 0.001
WHO grad 1 1.71 0.83 3.51 0.14
WHO grad 2 11.96 3.40 42.12 <0.001
Alcoholism No 1
Yes 2.37 1.16 4.84 0.018
Type of esophagectomy Transthoracic 1
Transhiatal 1.20 0.57 2.55 0.63
Positive lymph nodes § 0 1 0.002
1-3 1.43 0.73 2.81 0.29
≥ 4 3.84 1.79 8.23 0.001
Treatment Surgery alone 1
Chemoradiotherapy + Surgery 1.02 0.50 2.07 0.95
† Hazard ratio. ‡ Confidence interval. § Number of lymph nodes with metastasis in the resected specimen.
Table 6: Site of first recurrence in 76 esophageal cancer patients.
Surgery alone, n = 45 Chemoradiotherapy + surgery, n = 31
† Locoregional failure 0 2 (6)
Distant metastasis 24 (53) 9 (29)
Local and distant simultaneously 3 (7) 3 (10)
No recurrence 11 (24) 12 (39)
R1 or R2 resections ‡ 7 (16) 5 (16)
† Locoregional failure stands for disease recurrence in the field of radiotherapy and/or field of surgery in the mediastinum. ‡ Remaining 
microscopic or macroscopic disease after surgery. Percentages are in parentheses.
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vival.
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